All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the Lymphoma, Leukemia & Myeloma 2021 Virtual Congress, the Lymphoma Hub was pleased to speak to Bruce Cheson, Georgetown University Hospital, Washington DC, US. We asked, What are the benefits of adding anti-CD20 therapy to treatment with targeted agents in chronic lymphocytic leukemia (CLL)?
What are the benefits of adding anti-CD20 therapy to treatment with targeted agents in CLL?
Cheson begins by highlighting two trials that failed to show an advantage when adding rituximab to ibrutinib and current second generation anti-CD20s e.g. Obinutuzumab, which are shown to have some advantages over rituximab. Finally, he discusses the GENUINE trial where ublituximab was found to be superior to ibrutinib.
New chemotherapy-free approaches for the treatment of lymphoid malignancies
At the 15th International Conference on Malignant Lymphoma, the Lymphoma Hub Satellite Symposium highlighted recent advances in chemotherapy-free options in the field of...
ASCO 2017 | CLL: results of the phase II CALGB 10404 and phase III GENUINE trials, and a retrospective analysis of Richter’s Transformation with novel agents
At the 2017 ASCO Annual Meeting, an oral abstract session took place where 3 key oral...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox